Mycobacterium Tuberculosis
Nitroimidazopyran PA-824 bactericidal against Mycobacterium Tuberculosis
Published in Blood Weekly, August 11th, 2005
"The nitroimidazopyran PA-824 has potent in vitro activity against Mycobacterium tuberculosis, a narrow spectrum of activity limited primarily to the M. tuberculosis complex, and no demonstrable cross-resistance to a variety, of antituberculosis drugs.
"In a series of experiments, we sequentially characterized the activity of PA-824 in an experimental murine model of tuberculosis," wrote investigators in the United States.
"The minimal effective dose was 12.5 mg/kg of body weight/day. The minimal bactericidal dose (MBD) was 100...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2005-08-11)
More Articles from Blood Weekly
- Spinal Cord Injury
Neural SCs delivered to injured cervical spinal cord by intrathecal injection - Stem Cell Transplantation
Autologous mesenchymal stem cell transplantation improves recovery after stroke - Stem Cell Transplantation
CD34+ cell dose plays role in preventing late infections in pediatric SCT - Tissue Engineering
Autologous epidermal cells induce wound closure of neurotrophic ulcerations - Tissue Engineering
Viable autologous semilunar heart valve can be created from stem cells - Hemophilus ducreyi
H. ducreyi dsrA mutant killed by normal human serum initiated by IgM binding - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
